New Insights on Endotoxic Septic Shock
TORONTO — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a pioneering theranostic company focused on innovative treatments for sepsis and septic shock, has recently published significant research findings that establish endotoxic septic shock (“ESS”) as a serious and distinct condition within the broader category of septic shock. These findings were highlighted in the esteemed journal Critical Care Explorations.
Understanding the EDEN Observational Study
The study, which was multi-centered and involved 90 patients, revealed alarming statistics: patients diagnosed with ESS, which was defined by specific criteria—the endotoxin activity assay (“EAA™”) reaching ? 0.6 along with a Multiple Organ Dysfunction Score (“MODS”) greater than 9 or a Sequential Organ Failure Assessment (“SOFA”) score exceeding 11—faced a staggering 28-day mortality rate of 57.1%. This mortality rate is over three times higher compared to patients suffering other forms of septic shock, highlighting the critical need for targeted care.
Expert Insights on the Findings
Dr. John Kellum, the Chief Medical Officer at Spectral Medical, emphasized the importance of these findings, stating, “Identifying endotoxin activity alongside organ dysfunction measures can pinpoint the very ill patients at the highest risk for mortality.” This insight can significantly impact the design of clinical trials and real-world treatments, particularly by emphasizing endotoxin removal therapies for those most likely to benefit.
Significance in Clinical Practice and Future Research
The published study provides robust validation for Spectral's personalized approach to treating septic shock. The Company's FDA-cleared EAA diagnostic tool enables healthcare professionals to quickly identify patients with heightened endotoxin activity. Coupled with the PMX hemoadsorption device, designed to cleanse the bloodstream of circulating endotoxin, it presents a comprehensive approach to managing sepsis. The criteria from this study precisely align with those utilized in Spectral's recent Tigris trial, which examined PMX therapy efficacy among patients exhibiting high endotoxin levels alongside notable organ dysfunction.
Potential for Therapeutic Advancements
By distinctly characterizing ESS as the riskiest subtype of septic shock patient, this recent study enhances the therapeutic landscape for sepsis treatments. This reinforces the therapeutic strategy of combining EAA diagnostics with PMX therapy to provide a tailored approach known as Targeted Rapid Endotoxin Adsorption (TREA) Therapy. The findings bolster Spectral’s upcoming submissions to the FDA, potentially leading to new commercialization prospects for PMX in the United States.
About Spectral Medical Inc.
Spectral is navigating its Phase 3 clinical trials, aiming for U.S. FDA approval for its innovative treatment device, Toraymyxin™ (“PMX”). This advanced therapeutic hemoperfusion system is designed to eliminate endotoxin, which is a significant instigator of sepsis, from the bloodstream, guided by the Company's FDA-cleared EAA diagnostic that assesses endotoxin levels in blood samples.
Currently, PMX enjoys therapeutic approval in regions including Japan and Europe, has been licensed by Health Canada, and boasts over 360,000 units sold globally, showcasing its safety and effectiveness. Spectral has held exclusive development and commercial rights in the U.S. for PMX since 2009, and was granted Breakthrough Device Designation in 2022, emphasizing its role in treating endotoxic septic shock. Each year, around 330,000 patients in North America are diagnosed with septic shock, underscoring the device's potential impact on public health.
The Tigris Trial and Future Prospects
The Tigris Trial serves as a crucial confirmatory study analyzing PMX in conjunction with standard care, as opposed to standard care alone. Designed as a randomized trial with a 2:1 patient ratio, it uses Bayesian statistics to evaluate outcomes. Given the severe nature of endotoxic septic shock, this endeavor represents a significant commitment to improving treatment protocols for one of today’s critical health challenges.
Frequently Asked Questions
What is the main finding of the EDEN observational study?
The study found that patients with endotoxic septic shock (ESS) have a significantly higher mortality rate, underscoring the need for targeted treatment approaches.
How does Spectral Medical contribute to sepsis treatment?
Spectral Medical focuses on theranostics, aiming to enhance patient outcomes through customized treatment strategies combining diagnostics and therapies for sepsis.
What is the significance of the EAA diagnostic?
The EAA diagnostic tool allows for rapid identification of elevated endotoxin levels in patients, facilitating timely and appropriate treatment interventions.
What future trials are on the horizon for Spectral?
The Tigris Trial aims to confirm the effectiveness of the PMX device in treating septic shock, providing a basis for potential FDA approval and wider adoption of the therapy.
How does PMX work in treating septic shock?
PMX is designed to remove endotoxins from the bloodstream, thereby targeting the root cause of septic shock and potentially improving patient survival rates.
